FDA Approves MORPHINE SULFATE EXTENDED RELEASE — Rhodes Pharmaceuticals LLC
Rhodes Pharmaceuticals announced the FDA approval of its Morphine Sulfate Extended Release tablets, adding a high-volume product to its generic portfolio. This clearance positions the company to capture market share and compete within the lucrative chronic pain management sector.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day